Dark

Check out our API

CYTR
CYTRX CORP
stock OTC

Inactive

Oct 5, 2022

0.0920USD0.000%(0.0000)4,048

Pre-market

0.00USD-100.000%(-0.09)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 18, 2022

08:00AM EST CytRx to Hold Town Hall for Stockholders on Thursday, January 20th Business Wire

Jan 7, 2022

08:00AM EST CytRx to Participate in the H.C. Wainwright BioConnect Virtual Conference Business Wire

Jan 3, 2022

08:12AM EST CytRx Appoints Stephen Snowdy As CEO, Effective January 10 RTTNews

08:00AM EST CytRx Announces the Appointment of Dr. Stephen Snowdy as Chief Executive Officer Business Wire

Dec 21, 2021

08:06AM EST CytRx Highlights ImmunityBio's Use Of Aldoxorubicin In Ongoing Clinical Studies For Various Forms Of Cancer RTTNews

Nov 30, 2021

08:00AM EST CytRx Provides a Bold Vision on Centurion BioPharma's Plans for a State-of-the-Art Cancer Center in Las Vegas, Nevada Business Wire

Nov 12, 2021

08:00AM EST CytRx Comments on Quarterly Results and Recent Strategic Initiatives Business Wire

Nov 9, 2021

08:00AM EST CytRx Announces Centurion BioPharma Has Been Invited to Present Plans for a State-of-the-Art Cancer Center in Las Vegas, Nevada Business Wire

Nov 2, 2021

08:29AM EDT CytRx Highlights Orphazyme's Update On Productive Meeting With FDA On Arimoclomol In Niemann-Pick Disease Type C RTTNews

08:00AM EDT CytRx Highlights Orphazyme's Update on Productive Meeting with FDA Regarding Arimoclomol in Niemann-Pick Disease Type C Business Wire

Oct 14, 2021

08:00AM EDT CytRx Highlights ImmunityBio's Completion of Enrollment in Phase 2 Study of Advanced Metastatic Pancreatic Cancer Treatment Business Wire

Oct 5, 2021

08:00AM EDT CytRx to Present at Upcoming Virtual LD Micro Conference Business Wire

Sep 8, 2021

08:00AM EDT CytRx to Present at the H.C. Wainwright 23rd Annual Global Investment Conference Business Wire

Aug 24, 2021

09:37AM EDT CytRx Highlights Orphazyme's Published Results From Its Phase 2/3 Trial Of Arimoclomol In Niemann-Pick Disease Type C Benzinga

08:05AM EDT CytRx Highlights Orphazyme's Published Results From Phase 2/3 Trial Of Arimoclomol In Niemann-Pick Disease Type C RTTNews

08:00AM EDT CytRx Highlights Orphazyme's Published Results From Its Phase 2/3 Trial of Arimoclomol in Niemann-Pick Disease Type C Business Wire

Aug 12, 2021

04:06PM EDT CytRx Comments on Quarterly Results and Recent Strategic Initiatives Business Wire

Jul 29, 2021

04:05PM EDT CytRx Announces Director Election Results from 2021 Annual Meeting of Stockholders Business Wire

08:14AM EDT CytRx Highlights Preliminary Results Of Cohort C Of QUILT 88, Phase 2 Pancreatic Cancer Trial RTTNews

08:00AM EDT CytRx Highlights Preliminary Results of Cohort C of QUILT 88, a Phase 2 Pancreatic Cancer Trial That Includes Aldoxorubicin, Expected to be Released in Q1 2022 Business Wire

Jul 20, 2021

09:16AM EDT These OTC Securities Had the Most Trading Activity in June Benzinga

Jul 16, 2021

08:00AM EDT CytRx Corporation Announces Closing of $10 Million Offering to Healthcare-Focused Institutional Investor Business Wire

Jul 13, 2021

08:00AM EDT CytRx Corporation Enters Into Securities Purchase Agreement for $10 Million With Healthcare-Focused Institutional Investor Business Wire

Jun 30, 2021

08:28AM EDT CytRx Comments On Orphazyme's Promising 24-Month Interim Trial Results Of Arimoclomol For Niemann-Pick Disease Type C RTTNews

Jun 18, 2021

04:30PM EDT CytRx Comments On Orphazyme Complete Response Letter From FDA Benzinga

04:30PM EDT CytRx Notes Orphazyme's Regulatory Update from the FDA on Arimoclomol for Niemann-Pick Disease Type C Business Wire

06:28AM EDT Orphazyme Wild Party At Risk As FDA Rejects Its Rare Neurodegenerative Disease Drug Benzinga

Jun 17, 2021

08:33AM EDT The Daily Biotech Pulse: Biogen Faces Another Clinical Setback, CureVac's COVID-19 Vaccine Study Fails, Moment Of Reckoning For Orphazyme Benzinga

Jun 2, 2021

10:38AM EDT Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates Benzinga

08:00AM EDT CytRx to Present at Upcoming Investor Conferences Business Wire

Jun 1, 2021

05:31PM EDT Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates Benzinga

May 13, 2021

08:00AM EDT CytRx Comments on Quarterly Results and Year-to-Date Progress Business Wire

May 7, 2021

04:00PM EDT CytRx Notes Topline Data From Trial of Arimoclomol in Amyotrophic Lateral Sclerosis Business Wire

Apr 1, 2021

04:30PM EDT CytRx Notes Orphazyme's Announcement of Topline Results from Trial for Arimoclomol in the Treatment of Inclusion Body Myositis Business Wire

Mar 25, 2021

08:00AM EDT CytRx Comments on Fiscal Year 2020 Results and Highlights Strategic Progress Business Wire

Mar 8, 2021

08:46AM EST CytRx Highlights Orphazyme's Momentum Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type C Business Wire

Mar 4, 2021

08:00AM EST CytRx Highlights Orphazyme's Appointment of New CEO Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type C Business Wire

Mar 3, 2021

08:00AM EST CytRx to Participate in Upcoming Investor Conferences Business Wire

Feb 11, 2021

08:00AM EST CytRx is Added to the LD Micro Index Business Wire

Jan 15, 2021

08:01AM EST CytRx Highlights Use of Aldoxorubicin in Phase 2 Clinical Trials Yielding Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Patients Business Wire

Dec 31, 2020

02:00PM EST CytRx Issues Statement Regarding U.S. Regulatory Review of Arimoclomol for Niemann-Pick Disease Type C Business Wire

Dec 22, 2020

08:25AM EST CytRx Welcomes ImmunityBio And NantKwest On Their Proposed Merger RTTNews

08:00AM EST CytRx Comments on Proposed Combination of ImmunityBio and NantKwest Business Wire

Dec 7, 2020

10:50AM EST CytRx Announces Orphazyme's U.S. Expansion Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type C Business Wire

Nov 16, 2020

08:00AM EST CytRx Comments on Quarterly Results and Recent Strategic Progress Business Wire

Nov 11, 2020

08:10AM EST CytRx Highlights Orphazyme's Submission Of European Marketing Authorisation For Arimoclomol RTTNews

08:00AM EST CytRx Highlights Orphazyme's Submission of European Marketing Authorisation for Arimoclomol to Treat Niemann-Pick Disease Type C Business Wire

Oct 27, 2020

08:00AM EDT CytRx Highlights Orphazyme's Acceleration of Pre-Launch Activities for Arimoclomol Business Wire

Oct 13, 2020

08:00AM EDT CytRx Highlights Use of Licensed Drug Aldoxorubicin in ImmunityBio's Expanded Phase 2 Study of Pancreatic Cancer Treatment Business Wire

Oct 7, 2020

08:00AM EDT CytRx Highlights Use of Licensed Drug Aldoxorubicin in Treatment of Former Senate Majority Leader Harry Reid's Pancreatic Cancer Business Wire

Sep 30, 2020

08:25AM EDT CytRx Issues Statement Regarding Orphazyme's Global Offering Benzinga

Sep 17, 2020

08:11AM EDT CytRx Highlights Orphazyme's Receipt Of FDA Acceptance Of NDA For Arimoclomol For Niemann-Pick Disease Type C RTTNews

08:00AM EDT CytRx Highlights Orphazyme's Receipt of FDA Acceptance and Priority Review of its New Drug Application for arimoclomol for Niemann-Pick disease Type C Business Wire

Sep 3, 2020

04:00PM EDT CytRx Announces Voting Results from 2020 Annual Meeting and Issues New Investor Presentation Business Wire

Aug 24, 2020

08:00AM EDT CytRx Announces Initiatives to Strengthen Corporate Governance and Support Strategic Priorities Business Wire

Aug 13, 2020

08:32AM EDT CytRx's Board Sends Letter To Stockholders To Expose Dissident Investor And His Misguided Campaign RTTNews

08:00AM EDT CytRx's Board of Directors Sends Important Letter to Stockholders to Expose Dissident Investor and his Misguided Campaign Business Wire

Aug 10, 2020

08:01AM EDT CytRx Files Definitive Proxy Statement and Sends Letter to Stockholders PR Newswire

Jul 21, 2020

09:13AM EDT CytRx Highlights Orphazyme'Completion Of Rolling Submission Of NDA With FDA For Arimoclomol In NiemannPick Disease TypeC RTTNews

09:03AM EDT its New Drug Application with the U.S. FDA for Arimoclomol in Niemann-Pick Disease Type-C PR Newswire

Jul 20, 2020

09:01AM EDT CytRx Corporation Highlights Orphazyme's Announcement of its Collaboration with PR Newswire

Share